Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer
18 Years
N/A
Male
Prostate Neoplasms
Trial Information
Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer
This is an open-label (identity of assigned study drug will be known) study to evaluate the
safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of
what a drug does to the body), and anti-tumor activities of abiraterone acetate (also known
as CB7630) in patients with HRPC. The study will be conducted in 2 phases (Phase 1 and Phase
2). In the first part of the study (Phase 1), the maximum tolerated dose (MTD) of
abiraterone acetate will be determined for use in the second part of the study (Phase 2)
where the number of patients who achieve at least a 50% decrease in prostate specific
antigen (PSA) during treatment with abiraterone acetate will be assessed (MTD from Phase 1).
Abiraterone acetate will be taken orally (by mouth) in fed and fasted patients once daily.
Doses of abiraterone acetate (starting at 250 mg up to a maximum of 2000 mg) will be taken
for 28-day treatment periods to determine the MTD. Patients will take MTD of abiraterone
acetate for up to twelve 28 day cycles (12 months; patients will be given the option of
staying on abiraterone acetate treatment if they are deriving benefit). In Phase 2,
prednisone or dexamethasone will be administered concurrently with abiraterone acetate.
Serial pharmacokinetic and pharmacodynamic samples will be collected and safety will be
monitored throughout the study.
Inclusion Criteria:
Phase 1
- Histologically confirmed adenocarcinoma of the prostate
- No prior therapy with chemotherapy for prostate cancer
- Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing
hormone (LHRH) analogues or orchiectomy
- Testosterone <50 ng/dL
- Progressive disease after androgen deprivation
- The presence of objective metastatic disease is NOT required for study eligibility
- Demonstrate disease progression after antiandrogen withdrawal
- Eastern Cooperative Oncology Group (ECOG) performance status score = 0-1
- Laboratory values within protocol-defined parameters
- Systolic blood pressure <160 mmHg and diastolic blood pressure <110mmHg documented on
at least 3 different days
- Baseline adrenocorticotropic hormone (ACTH) stimulation test demonstrating a peak
cortisol >18 µg/dL
- Agrees to protocol-defined use of effective contraception
- Life expectancy of >=12 weeks
Phase 2
- Same as Phase 1 criteria with addition of following criteria
- Neoadjuvant or adjuvant chemotherapy is only allowed if the last dose is >1 year from
Cycle 1 Day 1
- Target or non-target abnormalities must be present either on screening bone scan,
computed tomography or magnetic resonance imaging
- No prior treatment with ketoconazole for the management of androgen independent
prostate cancer
Exclusion Criteria:
Phase 1
- Therapy with other hormonal therapy, including any dose of megestrol acetate
(Megace), finasteride (Proscar), dutasteride (Avodart) any herbal product known to
decrease prostate specific antigen (PSA) levels (eg, saw palmetto and PC-SPES), or
any systemic corticosteroid within 4 weeks prior to first dose of study drug
- Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug
- Therapy with supplements or complementary medicines/botanicals within 4 weeks of
first dose of study drug, except for any combination of the following: conventional
multivitamin supplements, selenium, lycopene, soy supplements
- Prior radiation therapy completed <4 weeks prior to enrollment
- Prior chemotherapy for hormone refractory prostate cancer
- Any currently active second malignancy, other than non-melanoma skin cancer
- Systolic blood pressure >=160 mmHg or diastolic blood pressure >=110 mmHg measured on
at least 2 occasions
- NYHA Class III or IV congestive heart failure
- Myocardial infarction within the 6 months prior to the first dose of study drug
- Serious intercurrent infections or nonmalignant medical illnesses that are
uncontrolled
- Active psychiatric illnesses/social situations that would limit compliance with
protocol requirements
- Active or uncontrolled autoimmune disease that may require corticosteroid therapy
during study
Phase 2
- Same as phase 1 with the following addition
- Abnormal electrocardiogram, including any finding which would interfere with
assessment of intervals (patients with long QT syndrome, bundle branch blocks or
hemiblocks are prohibited)
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Phase 1: maximum tolerated dose of CB7630
Outcome Time Frame:
Up to Cycle 12, Day 28
Safety Issue:
Yes
Principal Investigator
Janssen Research & Development, LLC Clinical Trial
Investigator Role:
Study Director
Investigator Affiliation:
Janssen Research & Development, LLC
Authority:
United States: Food and Drug Administration
Study ID:
CR016969
NCT ID:
NCT00473746
Start Date:
June 2006
Completion Date:
December 2012
Related Keywords:
- Prostate Neoplasms
- Prostate neoplasms
- Hormone refractory prostate cancer
- Abiraterone acetate
- CB7630
- Neoplasms
- Prostatic Neoplasms
Name | Location |
|---|---|
| MD Anderson Cancer Center | Houston, Texas 77030-4096 |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
| Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
| UCSF Comprehensive Cancer Center | San Francisco, California 94115 |
| Fountain Valley, California 92708 | |
| Austin, Texas 78705 | |
| Boston, Massachusetts | |
| Massachussetts General Hospital Cancer Center | Boston, Massachusetts 02114 |
